Johnson & Johnson (JNJ) : Johnson & Johnson (JNJ) had a healthy money flow of $1.61 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $51.43 million, whereas, investors only sold shares worth $49.82 million on downticks. The stock closed the day with an up-down ratio of 1.03.The money flow in the block trades to the tune of $0.25 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $5.52 million worth of transactions were on upticks. A paltry $5.27 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 1.05. Johnson & Johnson (JNJ) stock slid $0.19 intraday and traded at 122.81, a change of -0.15% over previous days close. However, for the week, the company shares are -0.03% compared to previous weeks close.
Johnson & Johnson is up 11.8% in the last 3-month period. Year-to-Date the stock performance stands at 21.61%. Shares of Johnson & Johnson rose by 0.17% in the last five trading days and 5.57% for the last 4 weeks. In a related news, The officer (Exec VP, WW Chair, Med Devices), of Johnson & Johnson, Pruden Gary J had unloaded 9,735 shares at $116.03 per share in a transaction on June 7, 2016. The total value of transaction was $1,129,552. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Johnson & Johnson (NYSE:JNJ): stock turned positive on Monday. Though the stock opened at $123, the bulls momentum made the stock top out at $123.22 level for the day. The stock recorded a low of $122.44 and closed the trading day at $123.14, in the green by 0.11%. The total traded volume for the day was 6,599,199. The stock had closed at $123 in the previous days trading.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.